{
    "xml": "<topic id=\"PHP529\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/ciclosporin\" basename=\"ciclosporin\" title=\"CICLOSPORIN\">\n<title>CICLOSPORIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_499\" namespace=\"/interactions/list-of-drug-interactions/ciclosporin\">Ciclosporin</xref>\n</p>\n<data name=\"vtmid\">80906007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_729481638\" title=\"Calcineurin inhibitors and related drugs\">Calcineurin inhibitors and related drugs</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">  </data>\r\n<data name=\"domainOfEffect\">  </data>\r\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">Cyclosporin</p>\r\n</body>\n<topic id=\"PHP40130\" outputclass=\"drugAction\" rev=\"1.21\" parent=\"/drugs/ciclosporin\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Ciclosporin is a calcineurin inhibitor.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40102\" outputclass=\"indicationsAndDose\" rev=\"1.52\" parent=\"/drugs/ciclosporin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe acute ulcerative colitis refractory to corticosteroid treatment</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By continuous intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2&#8239;mg/kg, to be given over 24 hours, dose adjusted according to blood-ciclosporin concentration and response.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe active rheumatoid arthritis when conventional second-line therapy inappropriate or ineffective (administered on expert advice)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2.5&#8239;mg/kg daily in 2 divided doses, then increased if necessary up to 4&#8239;mg/kg after 6&#8239;weeks, dose increase, if required should be gradual, discontinue if response insufficient after 3 months, dose adjusted according to response for maintenance and treatment reviewed after 6 months (continue only if benefits outweigh risks).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Short-term treatment of severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 1.25&#8239;mg/kg twice daily (max. per dose 2.5&#8239;mg/kg twice daily) usually maximum 8 weeks but may be used for longer, if good initial response not achieved within 2 weeks, increase dose rapidly up to maximum.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Short-term treatment of very severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2.5&#8239;mg/kg twice daily usually maximum 8 weeks but may be used for longer.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe psoriasis where conventional therapy ineffective or inappropriate (administered on expert advice)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 1.25&#8239;mg/kg twice daily (max. per dose 2.5&#8239;mg/kg twice daily), increased gradually to maximum if no improvement within 1 month, initial dose of 2.5&#8239;mg/kg twice daily justified if condition requires rapid improvement; discontinue if inadequate response after 3 months at the optimum dose; max. duration of treatment usually 1 year unless other treatments cannot be used.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Organ transplantation (used alone)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8211;15&#8239;mg/kg, to be administered 4&#8211;12 hours before transplantation, followed by 10&#8211;15&#8239;mg/kg daily for 1&#8211;2 weeks postoperatively, then maintenance 2&#8211;6&#8239;mg/kg daily, reduce dose gradually to maintenance. Dose should be adjusted according to blood-ciclosporin concentration and renal function; dose is lower if given concomitantly with other immunosuppressant therapy (e.g corticosteroids); if necessary one-third corresponding oral dose can be given by intravenous infusion over 2&#8211;6hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Bone-marrow transplantation</p>\n<p outputclass=\"therapeuticIndication\">Prevention and treatment of graft-versus-host disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>3&#8211;5&#8239;mg/kg daily, to be administered over 2&#8211;6 hours from day before transplantation to 2 weeks postoperatively, alternatively (by mouth) 12.5&#8211;15&#8239;mg/kg daily, then (by mouth) 12.5&#8239;mg/kg daily for 3-6 months and then tailed off (may take up to a year after transplantation).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Nephrotic syndrome</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;mg/kg daily in 2 divided doses, for maintenance reduce to lowest effective dose according to proteinuria and serum creatinine measurements; discontinue after 3 months if no improvement in glomerulonephritis or glomerulosclerosis (after 6 months in membranous glomerulonephritis).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40071\" outputclass=\"unlicensedUse\" rev=\"1.19\" parent=\"/drugs/ciclosporin\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Not licensed for use in severe acute ulcerative colitis refractory to corticosteroid treatment</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40134\" outputclass=\"importantSafetyInformation\" rev=\"1.11\" parent=\"/drugs/ciclosporin\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Patients should be stabilised on a particular brand of oral ciclosporin because switching between formulations without close monitoring may lead to clinically important changes in blood-ciclosporin concentration.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40136\" outputclass=\"contraindications\" rev=\"1.34\" parent=\"/drugs/ciclosporin\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Abnormal renal function (in non-transplant indications)</ph>; <ph outputclass=\"contraindication\">malignancy (in non-transplant indications)</ph>; <ph outputclass=\"contraindication\">uncontrolled hypertension (in non-transplant indications)</ph>; <ph outputclass=\"contraindication\">uncontrolled infections (in non-transplant indications)</ph>; <ph outputclass=\"contraindication\">use with tacrolimus specifically contraindicated</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40143\" outputclass=\"cautions\" rev=\"1.36\" parent=\"/drugs/ciclosporin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Hyperuricaemia</ph>; <ph outputclass=\"caution\">in atopic dermatitis <i>Staphylococcus aureus</i> skin infections&#8212;not absolute contra-indication providing controlled (but avoid erythromycin unless no other alternative)</ph>; <ph outputclass=\"caution\">in atopic dermatitis allow herpes simplex infections to clear before starting (if they occur during treatment withdraw if severe)</ph>; <ph outputclass=\"caution\">in atopic dermatitis and psoriasis discontinue if lymphoproliferative disorder develops</ph>; <ph outputclass=\"caution\">in psoriasis treat patients with malignant or pre-malignant conditions of skin only after appropriate treatment (and if no other option)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40097\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/ciclosporin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (ciclosporin).</p>\n</sectiondiv>\n<sectiondiv>\n<p>For patients other than transplant recipients, preferably avoid other immunosuppressants (increased risk of infection and malignancies, including lymphoma and skin cancer).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40086\" outputclass=\"sideEffects\" rev=\"1.13\" parent=\"/drugs/ciclosporin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<title>General side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">anorexia</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">fatigue</ph>; <ph outputclass=\"sideEffect\">gingival hyperplasia</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hepatic dysfunction</ph>; <ph outputclass=\"sideEffect\">hypercholesterolaemia</ph>; <ph outputclass=\"sideEffect\">hyperkalaemia</ph>; <ph outputclass=\"sideEffect\">hyperlipidaemia</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">hypertrichosis</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">hypomagnesaemia</ph>; <ph outputclass=\"sideEffect\">muscle cramps</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">renal dysfunction (renal structural changes on long-term administration)</ph>; <ph outputclass=\"sideEffect\">tremor</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaemia</ph>; <ph outputclass=\"sideEffect\">oedema</ph>; <ph outputclass=\"sideEffect\">signs of encephalopathy</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">weight gain</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Gynaecomastia</ph>; <ph outputclass=\"sideEffect\">haemolytic uraemic syndrome</ph>; <ph outputclass=\"sideEffect\">hyperglycaemia</ph>; <ph outputclass=\"sideEffect\">menstrual disturbances</ph>; <ph outputclass=\"sideEffect\">micro-angiopathic haemolytic anaemia</ph>; <ph outputclass=\"sideEffect\">motor polyneuropathy</ph>; <ph outputclass=\"sideEffect\">muscle weakness</ph>; <ph outputclass=\"sideEffect\">myopathy</ph>; <ph outputclass=\"sideEffect\">pancreatitis</ph>; <ph outputclass=\"sideEffect\">visual disturbances secondary to benign intracranial hypertension</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"specificSideEffects\">\n<title>Specific side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"sideEffect\">anaphylaxis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Visual disturbances</p>\n<p>Discontinue if visual disturbances secondary to benign intracranial hypertension occur.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40095\" outputclass=\"pregnancy\" parent=\"/drugs/ciclosporin\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Crosses placenta.</p>\n<p>There is less experience of ciclosporin in pregnancy but it does not appear to be any more harmful than azathioprine. The use of ciclosporin during pregnancy needs to be supervised in specialist units.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40148\" outputclass=\"breastFeeding\" parent=\"/drugs/ciclosporin\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in milk&#8212;manufacturer advises avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40116\" outputclass=\"hepaticImpairment\" parent=\"/drugs/ciclosporin\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Dosage adjustment based on bilirubin and liver enzymes may be needed.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40092\" outputclass=\"renalImpairment\" parent=\"/drugs/ciclosporin\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>In patients with nephrotic syndrome and renal impairment initially 2.5&#8239;mg/kg daily. Reduce dose by 25&#8211;50% if serum creatinine more than 30% above baseline on more than one measurement.</p>\n</sectiondiv>\n<sectiondiv>\n<p>In rheumatoid arthritis, reduce dose if serum creatinine increases more than 30% above baseline in more than 1 measurement; if above 50%, reduce dose by 50% (even if within normal range) and discontinue if reduction not successful within 1 month.</p>\n</sectiondiv>\n<sectiondiv>\n<p>In psoriasis and atopic dermatitis, reduce dose by 25&#8211;50% if serum creatinine increases more than 30% above baseline (even if within normal range) and discontinue if reduction not successful within 1 month.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40088\" outputclass=\"preTreatmentScreening\" rev=\"1.34\" parent=\"/drugs/ciclosporin\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p>In psoriasis, exclude malignancies (including those of skin and cervix) before starting (biopsy any lesions not typical of psoriasis).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40067\" outputclass=\"monitoringRequirements\" parent=\"/drugs/ciclosporin\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Dermatological and physical examination, including blood pressure and renal function measurements required at least twice before starting treatment for psoriasis or atopic dermatitis.</p>\n<p>Monitor liver function.</p>\n<p>Monitor serum potassium especially in renal dysfunction (risk of hyperkalaemia).</p>\n<p>Monitor serum magnesium.</p>\n<p>Measure blood lipids before treatment and after the first month of treatment.</p>\n<p>In psoriasis and atopic dermatitis monitor serum creatinine every 2 weeks for first 3 months then every month.</p>\n<p>Investigate lymphadenopathy that persists despite improvement in atopic dermatitis.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor kidney function&#8212;dose dependent increase in serum creatinine and urea during first few weeks may necessitate dose reduction in transplant patients (exclude rejection if kidney transplant) or discontinuation in non-transplant patients.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor blood pressure&#8212;discontinue if hypertension develops that cannot be controlled by antihypertensives.</p>\n</sectiondiv>\n<sectiondiv>\n<p>In long-term management of nephrotic syndrome, perform renal biopsies at yearly intervals.</p>\n</sectiondiv>\n<sectiondiv>\n<p>In rheumatoid arthritis measure serum creatinine at least twice before treatment. During treatment, monitor serum creatinine every 2 weeks for first 3 months, then every month for a further 3 months, then every 4&#8211;8 weeks depending on the stability of the disease, concomitant medication, and concomitant diseases (or more frequently if dose increased or concomitant NSAIDs introduced or increased).</p>\n<p>Monitor hepatic function if concomitant NSAIDs given.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40157\" outputclass=\"directionsForAdministration\" rev=\"1.25\" parent=\"/drugs/ciclosporin\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use</p>\n<p>Mix solution with orange juice (or squash) or apple juice (to improve taste) or with water immediately before taking (and rinse with more to ensure total dose). Do not mix with grapefruit juice.</p>\n<p>With capsules and oral solution, total daily dose should be taken in 2 divided doses.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Sandimmun</i>\n<tm tmtype=\"reg\"/>), give intermittently <i>or</i> continously <i>in</i> Glucose 5% <i>or</i> Sodium Chloride 0.9%; dilute to a concentration of 50&#8239;mg in 20&#8211;100&#8239;mL; give intermittent infusion over 2&#8211;6 hours; not to be used with PVC equipment.</p>\n<p>Observe patient for signs of anaphylaxis for at least 30 minutes after starting infusion and at frequent intervals thereafter.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59703\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.13\" parent=\"/drugs/ciclosporin\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Brand name prescribing</p>\n<p>Prescribing and dispensing of ciclosporin should be by brand name to avoid inadvertent switching. If it is necessary to switch a patient to a different brand of ciclosporin, the patient should be monitored closely for changes in blood-ciclosporin concentration, serum creatinine, blood pressure, and transplant function.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use</p>\n<p>\n<i>Sandimmun</i>\n<tm tmtype=\"reg\"/> capsules and oral solution are available direct from Novartis for patients who cannot be transferred to a different oral preparation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40127\" outputclass=\"handlingAndStorage\" rev=\"1.11\" parent=\"/drugs/ciclosporin\">\n<title>Handling and storage</title>\n<body>\n<section>\n<sectiondiv>\n<p>Keep medicine measure away from other liquids (including water).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40094\" outputclass=\"patientAndCarerAdvice\" rev=\"1.41\" parent=\"/drugs/ciclosporin\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use</p>\n<p>Patients and carers should be counselled on the administration of ciclosporin capsules and oral solution.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Avoid excessive exposure to UV light, including sunlight. In psoriasis and atopic dermatitis, avoid use of UVB or PUVA.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP529-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ciclosporin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: eye drops, eye ointment</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75375\" title=\"Capsule\" namespace=\"/drugs/ciclosporin/capsule\">Capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75523\" title=\"Oral solution\" namespace=\"/drugs/ciclosporin/oral-solution\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75438\" title=\"Solution for infusion\" namespace=\"/drugs/ciclosporin/solution-for-infusion\">Solution for infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75598\" title=\"Eye drops\" namespace=\"/drugs/ciclosporin/eye-drops\">Eye drops</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP97237\" namespace=\"/guidance/adverse-reactions-to-drugs\" title=\"Adverse reactions to drugs\" count=\"1\" rel=\"backlink\">Adverse reactions to drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78151\" namespace=\"/treatment-summaries/immune-response\" title=\"Immune response\" count=\"5\" rel=\"backlink\">Immune response</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78316\" namespace=\"/treatment-summaries/inflammatory-bowel-disease\" title=\"Inflammatory bowel disease\" count=\"2\" rel=\"backlink\">Inflammatory bowel disease</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78319\" namespace=\"/treatment-summaries/psoriasis\" title=\"Psoriasis\" count=\"1\" rel=\"backlink\">Psoriasis</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78375\" namespace=\"/treatment-summaries/eczema-and-psoriasis-drugs-affecting-the-immune-response\" title=\"Eczema and psoriasis, drugs affecting the immune response\" count=\"1\" rel=\"backlink\">Eczema and psoriasis, drugs affecting the immune response</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78421\" namespace=\"/treatment-summaries/rheumatic-disease-suppressing-drugs\" title=\"Rheumatic disease, suppressing drugs\" count=\"3\" rel=\"backlink\">Rheumatic disease, suppressing drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78505\" namespace=\"/treatment-summaries/neuromuscular-disorders\" title=\"Neuromuscular disorders\" count=\"1\" rel=\"backlink\">Neuromuscular disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78556\" namespace=\"/treatment-summaries/platelet-disorders\" title=\"Platelet disorders\" count=\"1\" rel=\"backlink\">Platelet disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78590\" namespace=\"/treatment-summaries/anaemias\" title=\"Anaemias\" count=\"1\" rel=\"backlink\">Anaemias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78614\" namespace=\"/treatment-summaries/arthritis\" title=\"Arthritis\" count=\"1\" rel=\"backlink\">Arthritis</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_499\" namespace=\"/interactions/list-of-drug-interactions/ciclosporin\" title=\"Ciclosporin\" count=\"1\" rel=\"link\">Ciclosporin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75375\" namespace=\"/drugs/ciclosporin/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75523\" namespace=\"/drugs/ciclosporin/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75438\" namespace=\"/drugs/ciclosporin/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75598\" namespace=\"/drugs/ciclosporin/eye-drops\" title=\"Eye drops\" count=\"1\" rel=\"link\">Eye drops</xref>\n</links>\n</topic>",
    "id": "PHP529",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/ciclosporin",
    "basename": "ciclosporin",
    "title": "CICLOSPORIN",
    "interactants": [
        {
            "id": "bnf_int_499",
            "label": "Ciclosporin"
        }
    ],
    "vtmid": "80906007",
    "drugClassification": [
        "Calcineurin inhibitors and related drugs"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Cyclosporin"
    ],
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Ciclosporin is a calcineurin inhibitor.",
                "html": "<p>Ciclosporin is a calcineurin inhibitor.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Severe acute ulcerative colitis refractory to corticosteroid treatment",
                        "html": "Severe acute ulcerative colitis refractory to corticosteroid treatment"
                    }
                ],
                "specificity": {
                    "routes": [
                        "continuous intravenous infusion"
                    ],
                    "textContent": "By continuous intravenous infusion",
                    "html": "By continuous intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "2 mg/kg, to be given over 24 hours, dose adjusted according to blood-ciclosporin concentration and response.",
                        "html": "<p>2&#8239;mg/kg, to be given over 24 hours, dose adjusted according to blood-ciclosporin concentration and response.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe active rheumatoid arthritis when conventional second-line therapy inappropriate or ineffective (administered on expert advice)",
                        "html": "Severe active rheumatoid arthritis when conventional second-line therapy inappropriate or ineffective (administered on expert advice)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 2.5 mg/kg daily in 2 divided doses, then increased if necessary up to 4 mg/kg after 6 weeks, dose increase, if required should be gradual, discontinue if response insufficient after 3 months, dose adjusted according to response for maintenance and treatment reviewed after 6 months (continue only if benefits outweigh risks).",
                        "html": "<p>Initially 2.5&#8239;mg/kg daily in 2 divided doses, then increased if necessary up to 4&#8239;mg/kg after 6&#8239;weeks, dose increase, if required should be gradual, discontinue if response insufficient after 3 months, dose adjusted according to response for maintenance and treatment reviewed after 6 months (continue only if benefits outweigh risks).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Short-term treatment of severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)",
                        "html": "Short-term treatment of severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 1.25 mg/kg twice daily (max. per dose 2.5 mg/kg twice daily) usually maximum 8 weeks but may be used for longer, if good initial response not achieved within 2 weeks, increase dose rapidly up to maximum.",
                        "html": "<p>Initially 1.25&#8239;mg/kg twice daily (max. per dose 2.5&#8239;mg/kg twice daily) usually maximum 8 weeks but may be used for longer, if good initial response not achieved within 2 weeks, increase dose rapidly up to maximum.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Short-term treatment of very severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)",
                        "html": "Short-term treatment of very severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 2.5 mg/kg twice daily usually maximum 8 weeks but may be used for longer.",
                        "html": "<p>Initially 2.5&#8239;mg/kg twice daily usually maximum 8 weeks but may be used for longer.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe psoriasis where conventional therapy ineffective or inappropriate (administered on expert advice)",
                        "html": "Severe psoriasis where conventional therapy ineffective or inappropriate (administered on expert advice)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 1.25 mg/kg twice daily (max. per dose 2.5 mg/kg twice daily), increased gradually to maximum if no improvement within 1 month, initial dose of 2.5 mg/kg twice daily justified if condition requires rapid improvement; discontinue if inadequate response after 3 months at the optimum dose; max. duration of treatment usually 1 year unless other treatments cannot be used.",
                        "html": "<p>Initially 1.25&#8239;mg/kg twice daily (max. per dose 2.5&#8239;mg/kg twice daily), increased gradually to maximum if no improvement within 1 month, initial dose of 2.5&#8239;mg/kg twice daily justified if condition requires rapid improvement; discontinue if inadequate response after 3 months at the optimum dose; max. duration of treatment usually 1 year unless other treatments cannot be used.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Organ transplantation (used alone)",
                        "html": "Organ transplantation (used alone)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "10&#8211;15 mg/kg, to be administered 4&#8211;12 hours before transplantation, followed by 10&#8211;15 mg/kg daily for 1&#8211;2 weeks postoperatively, then maintenance 2&#8211;6 mg/kg daily, reduce dose gradually to maintenance. Dose should be adjusted according to blood-ciclosporin concentration and renal function; dose is lower if given concomitantly with other immunosuppressant therapy (e.g corticosteroids); if necessary one-third corresponding oral dose can be given by intravenous infusion over 2&#8211;6hours.",
                        "html": "<p>10&#8211;15&#8239;mg/kg, to be administered 4&#8211;12 hours before transplantation, followed by 10&#8211;15&#8239;mg/kg daily for 1&#8211;2 weeks postoperatively, then maintenance 2&#8211;6&#8239;mg/kg daily, reduce dose gradually to maintenance. Dose should be adjusted according to blood-ciclosporin concentration and renal function; dose is lower if given concomitantly with other immunosuppressant therapy (e.g corticosteroids); if necessary one-third corresponding oral dose can be given by intravenous infusion over 2&#8211;6hours.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Bone-marrow transplantation",
                        "html": "Bone-marrow transplantation"
                    },
                    {
                        "textContent": "Prevention and treatment of graft-versus-host disease",
                        "html": "Prevention and treatment of graft-versus-host disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous infusion"
                    ],
                    "textContent": "Initially by intravenous infusion",
                    "html": "Initially by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "3&#8211;5 mg/kg daily, to be administered over 2&#8211;6 hours from day before transplantation to 2 weeks postoperatively, alternatively (by mouth) 12.5&#8211;15 mg/kg daily, then (by mouth) 12.5 mg/kg daily for 3-6 months and then tailed off (may take up to a year after transplantation).",
                        "html": "<p>3&#8211;5&#8239;mg/kg daily, to be administered over 2&#8211;6 hours from day before transplantation to 2 weeks postoperatively, alternatively (by mouth) 12.5&#8211;15&#8239;mg/kg daily, then (by mouth) 12.5&#8239;mg/kg daily for 3-6 months and then tailed off (may take up to a year after transplantation).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Nephrotic syndrome",
                        "html": "Nephrotic syndrome"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "5 mg/kg daily in 2 divided doses, for maintenance reduce to lowest effective dose according to proteinuria and serum creatinine measurements; discontinue after 3 months if no improvement in glomerulonephritis or glomerulosclerosis (after 6 months in membranous glomerulonephritis).",
                        "html": "<p>5&#8239;mg/kg daily in 2 divided doses, for maintenance reduce to lowest effective dose according to proteinuria and serum creatinine measurements; discontinue after 3 months if no improvement in glomerulonephritis or glomerulosclerosis (after 6 months in membranous glomerulonephritis).</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Not licensed for use in severe acute ulcerative colitis refractory to corticosteroid treatment",
                "html": "<p>Not licensed for use in severe acute ulcerative colitis refractory to corticosteroid treatment</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "textContent": "Patients should be stabilised on a particular brand of oral ciclosporin because switching between formulations without close monitoring may lead to clinically important changes in blood-ciclosporin concentration.",
                "html": "<p>Patients should be stabilised on a particular brand of oral ciclosporin because switching between formulations without close monitoring may lead to clinically important changes in blood-ciclosporin concentration.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Abnormal renal function (in non-transplant indications)",
                "html": "Abnormal renal function (in non-transplant indications)"
            },
            {
                "type": "contraindications",
                "textContent": "malignancy (in non-transplant indications)",
                "html": "malignancy (in non-transplant indications)"
            },
            {
                "type": "contraindications",
                "textContent": "uncontrolled hypertension (in non-transplant indications)",
                "html": "uncontrolled hypertension (in non-transplant indications)"
            },
            {
                "type": "contraindications",
                "textContent": "uncontrolled infections (in non-transplant indications)",
                "html": "uncontrolled infections (in non-transplant indications)"
            },
            {
                "type": "contraindications",
                "textContent": "use with tacrolimus specifically contraindicated",
                "html": "use with tacrolimus specifically contraindicated"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Hyperuricaemia",
                "html": "Hyperuricaemia"
            },
            {
                "type": "cautions",
                "textContent": "in atopic dermatitis Staphylococcus aureus skin infections&#8212;not absolute contra-indication providing controlled (but avoid erythromycin unless no other alternative)",
                "html": "in atopic dermatitis <i>Staphylococcus aureus</i> skin infections&#8212;not absolute contra-indication providing controlled (but avoid erythromycin unless no other alternative)"
            },
            {
                "type": "cautions",
                "textContent": "in atopic dermatitis allow herpes simplex infections to clear before starting (if they occur during treatment withdraw if severe)",
                "html": "in atopic dermatitis allow herpes simplex infections to clear before starting (if they occur during treatment withdraw if severe)"
            },
            {
                "type": "cautions",
                "textContent": "in atopic dermatitis and psoriasis discontinue if lymphoproliferative disorder develops",
                "html": "in atopic dermatitis and psoriasis discontinue if lymphoproliferative disorder develops"
            },
            {
                "type": "cautions",
                "textContent": "in psoriasis treat patients with malignant or pre-malignant conditions of skin only after appropriate treatment (and if no other option)",
                "html": "in psoriasis treat patients with malignant or pre-malignant conditions of skin only after appropriate treatment (and if no other option)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (ciclosporin).",
                "html": "<p>Appendix 1 (ciclosporin).</p>"
            },
            {
                "type": "general",
                "textContent": "For patients other than transplant recipients, preferably avoid other immunosuppressants (increased risk of infection and malignancies, including lymphoma and skin cancer).",
                "html": "<p>For patients other than transplant recipients, preferably avoid other immunosuppressants (increased risk of infection and malignancies, including lymphoma and skin cancer).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anorexia",
                        "html": "anorexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "fatigue",
                        "html": "fatigue",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gingival hyperplasia",
                        "html": "gingival hyperplasia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hepatic dysfunction",
                        "html": "hepatic dysfunction",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypercholesterolaemia",
                        "html": "hypercholesterolaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyperkalaemia",
                        "html": "hyperkalaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyperlipidaemia",
                        "html": "hyperlipidaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertrichosis",
                        "html": "hypertrichosis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypomagnesaemia",
                        "html": "hypomagnesaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "muscle cramps",
                        "html": "muscle cramps",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "renal dysfunction (renal structural changes on long-term administration)",
                        "html": "renal dysfunction (renal structural changes on long-term administration)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Anaemia",
                        "html": "Anaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "signs of encephalopathy",
                        "html": "signs of encephalopathy",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "weight gain",
                        "html": "weight gain",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Gynaecomastia",
                        "html": "Gynaecomastia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "haemolytic uraemic syndrome",
                        "html": "haemolytic uraemic syndrome",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hyperglycaemia",
                        "html": "hyperglycaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "menstrual disturbances",
                        "html": "menstrual disturbances",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "micro-angiopathic haemolytic anaemia",
                        "html": "micro-angiopathic haemolytic anaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "motor polyneuropathy",
                        "html": "motor polyneuropathy",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "muscle weakness",
                        "html": "muscle weakness",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "myopathy",
                        "html": "myopathy",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pancreatitis",
                        "html": "pancreatitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "visual disturbances secondary to benign intracranial hypertension",
                        "html": "visual disturbances secondary to benign intracranial hypertension",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        },
        "specific": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "anaphylaxis",
                        "html": "anaphylaxis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Visual disturbances",
                "textContent": "Discontinue if visual disturbances secondary to benign intracranial hypertension occur.",
                "html": "<p>Discontinue if visual disturbances secondary to benign intracranial hypertension occur.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Crosses placenta.\n\nThere is less experience of ciclosporin in pregnancy but it does not appear to be any more harmful than azathioprine. The use of ciclosporin during pregnancy needs to be supervised in specialist units.",
                "html": "<p>Crosses placenta.</p><p>There is less experience of ciclosporin in pregnancy but it does not appear to be any more harmful than azathioprine. The use of ciclosporin during pregnancy needs to be supervised in specialist units.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in milk&#8212;manufacturer advises avoid.",
                "html": "<p>Present in milk&#8212;manufacturer advises avoid.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Dosage adjustment based on bilirubin and liver enzymes may be needed.",
                "html": "<p>Dosage adjustment based on bilirubin and liver enzymes may be needed.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "In patients with nephrotic syndrome and renal impairment initially 2.5 mg/kg daily. Reduce dose by 25&#8211;50% if serum creatinine more than 30% above baseline on more than one measurement.",
                "html": "<p>In patients with nephrotic syndrome and renal impairment initially 2.5&#8239;mg/kg daily. Reduce dose by 25&#8211;50% if serum creatinine more than 30% above baseline on more than one measurement.</p>"
            },
            {
                "type": "doseAdjustments",
                "textContent": "In rheumatoid arthritis, reduce dose if serum creatinine increases more than 30% above baseline in more than 1 measurement; if above 50%, reduce dose by 50% (even if within normal range) and discontinue if reduction not successful within 1 month.",
                "html": "<p>In rheumatoid arthritis, reduce dose if serum creatinine increases more than 30% above baseline in more than 1 measurement; if above 50%, reduce dose by 50% (even if within normal range) and discontinue if reduction not successful within 1 month.</p>"
            },
            {
                "type": "doseAdjustments",
                "textContent": "In psoriasis and atopic dermatitis, reduce dose by 25&#8211;50% if serum creatinine increases more than 30% above baseline (even if within normal range) and discontinue if reduction not successful within 1 month.",
                "html": "<p>In psoriasis and atopic dermatitis, reduce dose by 25&#8211;50% if serum creatinine increases more than 30% above baseline (even if within normal range) and discontinue if reduction not successful within 1 month.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "textContent": "In psoriasis, exclude malignancies (including those of skin and cervix) before starting (biopsy any lesions not typical of psoriasis).",
                "html": "<p>In psoriasis, exclude malignancies (including those of skin and cervix) before starting (biopsy any lesions not typical of psoriasis).</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Dermatological and physical examination, including blood pressure and renal function measurements required at least twice before starting treatment for psoriasis or atopic dermatitis.\n\nMonitor liver function.\n\nMonitor serum potassium especially in renal dysfunction (risk of hyperkalaemia).\n\nMonitor serum magnesium.\n\nMeasure blood lipids before treatment and after the first month of treatment.\n\nIn psoriasis and atopic dermatitis monitor serum creatinine every 2 weeks for first 3 months then every month.\n\nInvestigate lymphadenopathy that persists despite improvement in atopic dermatitis.",
                "html": "<p>Dermatological and physical examination, including blood pressure and renal function measurements required at least twice before starting treatment for psoriasis or atopic dermatitis.</p><p>Monitor liver function.</p><p>Monitor serum potassium especially in renal dysfunction (risk of hyperkalaemia).</p><p>Monitor serum magnesium.</p><p>Measure blood lipids before treatment and after the first month of treatment.</p><p>In psoriasis and atopic dermatitis monitor serum creatinine every 2 weeks for first 3 months then every month.</p><p>Investigate lymphadenopathy that persists despite improvement in atopic dermatitis.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor kidney function&#8212;dose dependent increase in serum creatinine and urea during first few weeks may necessitate dose reduction in transplant patients (exclude rejection if kidney transplant) or discontinuation in non-transplant patients.",
                "html": "<p>Monitor kidney function&#8212;dose dependent increase in serum creatinine and urea during first few weeks may necessitate dose reduction in transplant patients (exclude rejection if kidney transplant) or discontinuation in non-transplant patients.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor blood pressure&#8212;discontinue if hypertension develops that cannot be controlled by antihypertensives.",
                "html": "<p>Monitor blood pressure&#8212;discontinue if hypertension develops that cannot be controlled by antihypertensives.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "In long-term management of nephrotic syndrome, perform renal biopsies at yearly intervals.",
                "html": "<p>In long-term management of nephrotic syndrome, perform renal biopsies at yearly intervals.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "In rheumatoid arthritis measure serum creatinine at least twice before treatment. During treatment, monitor serum creatinine every 2 weeks for first 3 months, then every month for a further 3 months, then every 4&#8211;8 weeks depending on the stability of the disease, concomitant medication, and concomitant diseases (or more frequently if dose increased or concomitant NSAIDs introduced or increased).\n\nMonitor hepatic function if concomitant NSAIDs given.",
                "html": "<p>In rheumatoid arthritis measure serum creatinine at least twice before treatment. During treatment, monitor serum creatinine every 2 weeks for first 3 months, then every month for a further 3 months, then every 4&#8211;8 weeks depending on the stability of the disease, concomitant medication, and concomitant diseases (or more frequently if dose increased or concomitant NSAIDs introduced or increased).</p><p>Monitor hepatic function if concomitant NSAIDs given.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With oral use",
                    "html": "With <ph outputclass=\"route\">oral</ph> use",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "Mix solution with orange juice (or squash) or apple juice (to improve taste) or with water immediately before taking (and rinse with more to ensure total dose). Do not mix with grapefruit juice.\n\nWith capsules and oral solution, total daily dose should be taken in 2 divided doses.",
                "html": "<p>Mix solution with orange juice (or squash) or apple juice (to improve taste) or with water immediately before taking (and rinse with more to ensure total dose). Do not mix with grapefruit juice.</p><p>With capsules and oral solution, total daily dose should be taken in 2 divided doses.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Sandimmun ), give intermittently or continously in Glucose 5% or Sodium Chloride 0.9%; dilute to a concentration of 50 mg in 20&#8211;100 mL; give intermittent infusion over 2&#8211;6 hours; not to be used with PVC equipment.\n\nObserve patient for signs of anaphylaxis for at least 30 minutes after starting infusion and at frequent intervals thereafter.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Sandimmun</i>\n<tm tmtype=\"reg\"/>), give intermittently <i>or</i> continously <i>in</i> Glucose 5% <i>or</i> Sodium Chloride 0.9%; dilute to a concentration of 50&#8239;mg in 20&#8211;100&#8239;mL; give intermittent infusion over 2&#8211;6 hours; not to be used with PVC equipment.</p><p>Observe patient for signs of anaphylaxis for at least 30 minutes after starting infusion and at frequent intervals thereafter.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "title": "Brand name prescribing",
                "textContent": "Prescribing and dispensing of ciclosporin should be by brand name to avoid inadvertent switching. If it is necessary to switch a patient to a different brand of ciclosporin, the patient should be monitored closely for changes in blood-ciclosporin concentration, serum creatinine, blood pressure, and transplant function.",
                "html": "<p>Prescribing and dispensing of ciclosporin should be by brand name to avoid inadvertent switching. If it is necessary to switch a patient to a different brand of ciclosporin, the patient should be monitored closely for changes in blood-ciclosporin concentration, serum creatinine, blood pressure, and transplant function.</p>"
            },
            {
                "type": "prescribingAndDispensingInformation",
                "specificity": {
                    "textContent": "With oral use",
                    "html": "With <ph outputclass=\"route\">oral</ph> use",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "Sandimmun capsules and oral solution are available direct from Novartis for patients who cannot be transferred to a different oral preparation.",
                "html": "<p>\n<i>Sandimmun</i>\n<tm tmtype=\"reg\"/> capsules and oral solution are available direct from Novartis for patients who cannot be transferred to a different oral preparation.</p>"
            }
        ]
    },
    "handlingAndStorage": {
        "handlingAndStorage": [
            {
                "type": "handlingAndStorage",
                "textContent": "Keep medicine measure away from other liquids (including water).",
                "html": "<p>Keep medicine measure away from other liquids (including water).</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "specificity": {
                    "textContent": "With oral use",
                    "html": "With <ph outputclass=\"route\">oral</ph> use",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "Patients and carers should be counselled on the administration of ciclosporin capsules and oral solution.",
                "html": "<p>Patients and carers should be counselled on the administration of ciclosporin capsules and oral solution.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "textContent": "Avoid excessive exposure to UV light, including sunlight. In psoriasis and atopic dermatitis, avoid use of UVB or PUVA.",
                "html": "<p>Avoid excessive exposure to UV light, including sunlight. In psoriasis and atopic dermatitis, avoid use of UVB or PUVA.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "eye drops",
                "eye ointment"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75375",
                "label": "Capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75523",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75438",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75598",
                "label": "Eye drops",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP97237",
                "label": "Adverse reactions to drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78151",
                "label": "Immune response",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78316",
                "label": "Inflammatory bowel disease",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78319",
                "label": "Psoriasis",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78375",
                "label": "Eczema and psoriasis, drugs affecting the immune response",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78421",
                "label": "Rheumatic disease, suppressing drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78505",
                "label": "Neuromuscular disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78556",
                "label": "Platelet disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78590",
                "label": "Anaemias",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78614",
                "label": "Arthritis",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_499",
                "label": "Ciclosporin",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75375",
                "label": "Capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75523",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75438",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75598",
                "label": "Eye drops",
                "type": "medicinalForm"
            }
        ]
    }
}